Estrogen Use in Protection From Cognitive Decline

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.

Official Title

Estrogen Use in Protection From Cognitive Decline

Eligibility Criteria

Ages Eligible for Study: 45 Years to 65 Years
Sexes Eligible for Study: Female
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - Women between the ages of 45 and 65 - Currently on hormone replacement - One year or more post complete cessation of menses - Willing to sign the Human Subject Protection Consent form prior to enrollment in the study - Willing to be randomized to continue or discontinue estrogen therapy - Adequately visually and auditorially acute to allow neuropsychological testing - Beyond 8 years of educational achievement to allow adequate neuropsychological testing - Willing to undergo brain imaging - At risk for cognitive decline, as defined by one or more of the following: Personal or family history of mood disorder, Hypothyroidism, Diabetes, Family history of Alzheimer's, APOE-4 allele
Exclusion Criteria:
  1. - Diagnosis of possible or probable Alzheimer's disease or dementia - Cerebrovascular disease or uncontrolled hypertension (systolic BP >170 or diastolic BP >100) - History of myocardial infarction within previous year or unstable heart disease - History of significant liver disease, pulmonary disease, or current cancer - Contraindication for MRI (metal in body, claustrophobia, etc.)


Natalie L. Rasgon
Natalie L. Rasgon
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult) at the Stanford University Medical Center, Emerita
Jerome Yesavage